Department of Infectious Diseases, Medical Microbiology and Hygiene, Heidelberg University Hospital, Heidelberg, Germany.
Tropenklinik, Paul-Lechler-Krankenhaus, Tübingen, Germany.
Clin Microbiol Infect. 2015 Dec;21(12):1095.e5-9. doi: 10.1016/j.cmi.2015.08.021. Epub 2015 Sep 4.
To investigate the global occurrence of trimethoprim-sulfamethoxazole resistance and the genetic mechanisms of trimethoprim resistance, we analysed Staphylococcus aureus from travel-associated skin and soft-tissue infections treated at 13 travel clinics in Europe. Thirty-eight per cent (75/196) were trimethoprim-resistant and 21% (41/196) were resistant to trimethoprim-sulfamethoxazole. Among methicillin-resistant S. aureus, these proportions were 30% (7/23) and 17% (4/23), respectively. DfrG explained 92% (69/75) of all trimethoprim resistance in S. aureus. Travel to South Asia was associated with the highest risk of acquiring trimethoprim-sulfamethoxazole-resistant S. aureus. We conclude that globally dfrG is the predominant determinant of trimethoprim resistance in human S. aureus infection.
为了研究甲氧苄啶-磺胺甲恶唑耐药的全球发生情况和甲氧苄啶耐药的遗传机制,我们分析了欧洲 13 家旅行诊所治疗的与旅行相关的皮肤和软组织感染的金黄色葡萄球菌。38%(75/196)对甲氧苄啶耐药,21%(41/196)对甲氧苄啶-磺胺甲恶唑耐药。耐甲氧西林金黄色葡萄球菌的这两个比例分别为 30%(7/23)和 17%(4/23)。DfrG 解释了 69/75 株金黄色葡萄球菌中所有甲氧苄啶耐药的 92%。前往南亚旅行与获得甲氧苄啶-磺胺甲恶唑耐药金黄色葡萄球菌的风险最高。我们的结论是,全球范围内 dfrG 是人类金黄色葡萄球菌感染中甲氧苄啶耐药的主要决定因素。